News
EyePoint Pharmaceuticals' Duravyu shows promising Phase 2 results in DME, with potential for less frequent dosing. Check out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback